Behcet's Syndrome

Behcet's Syndrome

National Organization for Rare Disorders, Inc.

Important

It is possible that the main title of the report Behcet's Syndrome is not the name you expected. Please check the synonyms listing to find the alternate name(s) and disorder subdivision(s) covered by this report.

Synonyms

  • Adamantiades-Behcet's Syndrome
  • BD
  • Behcet's Disease
  • Oculo-Bucco-Genital Syndrome
  • Triple Symptom Complex of Behcet
  • Hulusi-Behcet's Syndrome

Disorder Subdivisions

  • None

General Discussion

Behcet's syndrome is a rare multisystem inflammatory disorder characterized by ulcers affecting the mouth and genitals, various skin lesions, and abnormalities affecting the eyes. Symptoms include areas of abnormal mucous membrane changes (lesions) of the mouth and genitals that tend to disappear and recur spontaneously. Inflammation of the eyes (anterior uveitis, posterior uveitis, or panuveitis) also affects individuals with Behcet's syndrome. Additional systems of the body may also be affected including the joints, blood vessels, central nervous system, and/or digestive tract. The exact cause of Behcet's syndrome is unknown.

Symptoms

The earliest symptom of Behcet's syndrome is usually painful canker sores on the mucous membranes that line the mouth (aphthous stomatitis). The sores are usually round or oval with reddish (erythematous) borders that may occur anywhere within the mouth. They may be shallow or deep and may appear as a single lesion or a cluster of multiple lesions. The sores typically heal within a few weeks without scarring, but frequently recur. They may precede other symptoms of Behcet's syndrome by a number of years. Sometimes similar sores may appear on the genitals, specifically the scrotum and shaft of the penis in males and the vulva in females. The sores are also round and painful, but may be larger and deeper than those affecting the mouth. These sores also recur, but, unlike oral sores, may tend to scar.



Behcet's syndrome also affects the eyes. Symptoms may include inflammation of the back of the eye (posterior uveitis) and inflammation of the anterior chamber (anterior uveitis or iridocyclitis). Inflammation of the iris accompanied by pain, tearing (lacrimation), and the accumulation of pus (hypopyon iritis) may also occur. The retina may become inflamed resulting in blurred vision, abnormal sensitivity to light (photophobia), and/or, inflammation of the thin membranous layer of blood vessels behind the retina (chorioretinitis). Although the lesions that cause inflammation in various parts of the eyes may resolve, repeated recurrences may result in the partial loss of vision (decreased visual acuity) or complete blindness if the disease is uncontrolled. In some cases, eye abnormalities may be the first symptom of Behcet's syndrome. In other cases, they may not develop until several years later.



Individuals with Behcet's syndrome may also exhibit the formation of small, pus-filled growths (pustules). Some affected individuals, especially females, may develop lesions that resemble those associated with erythema nodosum, a skin disorder characterized by the formation of tender, reddish, inflammatory nodules on the front of the legs. These nodules disappear on their own (spontaneously) sometimes leaving faint scars or discoloration (pigmentation). Some individuals with Behcet's syndrome, especially males, may develop small eruptions that resemble acne (acneiform eruptions) and/or inflammation that mistakingly appears to affect the hair follicles on the skin (pseudofolliculitis).



In approximately 50 percent of cases of Behcet's syndrome, affected individuals experience pain (arthralgia) and swelling in various joints of the body (polyarthritis). This may occur before, during, or after the onset of the other symptoms associated with Behcet's syndrome. Pain, which can range from mild to severe, typically affects the joints of the knees, wrists, elbows and ankles, and may become chronic. Lasting damage to affected joints is extremely rare.



Individuals with Behcet's syndrome may also have recurring ulcers in the digestive tract. Symptoms vary from mild abdominal discomfort to severe inflammation of the large intestine and rectum accompanied by diarrhea or bleeding.



Approximately 10%-20% of individuals with Behcet's syndrome also have involvement of the central nervous system. These symptoms usually appear months or years after the initial symptoms of Behcet's syndrome. Recurring attacks of inflammation of the membranes that surround the brain or spinal cord (meningitis or meningoencephalitis)can result in neurological damage. Symptoms may include headache, the inability to coordinate voluntary movement (cerebellar ataxia), impaired muscle movements of the face and throat (pseudobulbar palsies), stroke, and/or rarely, seizures.



Behcet's syndrome may also cause inflammation of the blood vessels (vasculitis). Inflammation of the large veins, particularly those in the legs, may occur along with the formation of blood clots (thrombophlebitis). The walls of an involved artery may bulge forming a sac and (aneurysm). In very rare cases, blood clots from the veins travel to the lungs (pulmonary emboli) resulting in episodes of chest pain, coughing, difficult or labored breathing (dypsnea), and coughing up blood (hemoptysis).



Unlike most diseases which are classified as a vasculitis, involvement of the kidneys or peripheral nerves is very rare.

Causes

The exact cause of Behcet's syndrome is not known. Studies suggest that some people may have a genetic predisposition to the condition. A genetic predisposition means that a person may carry a gene for a disease but it may not be expressed unless something in the environment triggers the disease. Researchers have demonstrated that certain individuals with Behcet's syndrome, especially those of Middle Eastern and Asian descent, have an increased frequency of certain "human leukocyte antigens" (HLAs) in the blood. Individuals with Behcet's syndrome are more likely to have HLA-B51 than the general population. The possible role of HLA-B51 in predisposing individuals to Behcet's syndrome and its overall association with the disorder is unknown.



Other research suggests that Behcet's syndrome may be an autoimmune disease. Autoimmune disorders are caused when the body's natural defenses against "foreign" or invading organisms (e.g., antibodies) begin to attack healthy tissue for unknown reasons. Viral or bacterial infections have also been suggested as a possible cause for the disorder.

Affected Populations

Behcet's syndrome is a rare disorder in the United States and Western Europe. It occurs most frequently in the Middle East and Asia, along ancient trading routes between the Mediterranean basin and eastern Asia, once known as the Silk Road. Turkey has the highest prevalence rate (80-370 cases per 100,000); Japan, Korea, China, Iran, and Saudi Arabi also have high prevalence rates. The disorder is the leading cause of blindness in Japan. The age of onset is typically between 30 and 40 years.



In the United States and Australia this syndrome is more common in women than men, and the symptoms tend to be less severe. Men may be more commonly affected in Middle Eastern countries and usually have more severe disease. Central nervous system involvement is more common among native populations of northern Europe and the United States.

Standard Therapies

Diagnosis

The diagnosis of Behcet's syndrome is made based on the clinical judgment of a physician. Criteria have been accepted, based upon the identification of recurrent oral ulcerations (aphthous stomatitis) that occur along with at least two of the following: eye lesions, skin lesions, and a positive pathergy test. (During a pathergy test, a physician pricks an individual with a sterile needle. A positive outcome occurs if a reddish spot (nodule or pustule) forms 48 hours after the prick.) However, these criteria have been formed so that patients might be included in clinical studies ("classification criteria") and are not really "diagnostic" criteria.



Treatment

The treatment of Behcet's syndrome is directed toward the specific symptoms that are apparent in each individual. Specific therapies for Behcet's syndrome are symptomatic and supportive.



Spontaneous remission is common for individuals with Behcet's syndrome. Corticosteroid-containing preparations may be applied to the affected areas may relieve the pain of ulcers. Mouthwashes that contain a local anesthetic, such as xylocaine, lidocaine, or Benadryl may temporarily relieve pain. Eye drops that contain corticosteroids may help relieve pain affecting the eyes. Continuing therapy with the drug colchicine may be effective in preventing recurring attacks of oral and genital ulcers or arthritis.



Inflammation of the joints, skin, and/or mucous membranes or other organs may be reduced with high-dose oral corticosteroid drugs. However, corticosteroids do not prevent recurring episodes of symptoms and may not reduce damage when used by itself. Immunosuppressive agents such as azathioprine, methotrexate, cyclosporine, or chlorambucil may be employed to control difficult inflammation and reduce damage. Experience is evolving with the use of interferon-alpha and with agents which inhibit tumor necrosis factor (TNF) in the treatment of Behcet's disease.



Arthritis associated with Behcet's syndrome may also be treated with cholchicine and nonsteroidal anti-inflammatory drugs (NSAIDs). Sulfasalazine and corticosteroids may be administered to treat inflammatory bowel disease and gastrointestinal lesions associated with Behcet's syndrome. Central nervous systems and vascular abnormalities may be treated with corticosteroids as well, often in conjunction with immunosuppressive agents. Anticoagulants should be considered in patients with clotting of major blood vessels.

Investigational Therapies

Immunosuppressive drugs such as azathioprine (Imuran), chlorambucil (Leukeran), cyclophosphamide (Cytoxan), and cyclosporine (Sandimmune) have being studied for use as treatments for Behcet's syndrome. It has been suggested that cyclosporine may be beneficial for the treatment of oral ulcers, skin lesions, and inflammation of the eyes, but the symptoms of Behcet's syndrome return quickly when the drug is stopped. Azathioprine (Imuran) has been used to control the progression of eye disease in people with Behcet's syndrome.



Information on current clinical trials is posted on the Internet at www.clinicaltrials.gov. All studies receiving U.S. Government funding, and some supported by private industry, are posted on this government web site.



For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:



Tollfree: (800) 411-1222

TTY: (866) 411-1010

Email: prpl@cc.nih.gov



For information about clinical trials sponsored by private sources, contact:

www.centerwatch.com

References

McKusick VA, ed. Online Mendelian Inheritance in Man (OMIM). Baltimore. MD: The Johns Hopkins University; Behcet Syndrome. Entry No: 109650; Last Update:10/24/2003.



REVIEW ARTICLES



Sakane T, et al. Behcet's disease. N Engl J Med. 1999;341:1284-91.



Uzun S, Alpsoy E, Durdu M, et al. The clinical course of Behcet's disease in pregnancy: a retrospective analysis and review of the literature. J Dermatol. 2003;30:499-502.



Yazici H. Behcet's syndrome: an update. Curr Rheumatol Rep. 2003;5:195-99.



Hirohata S, Kikuchi H. Behcet's disease. Arthritis Res Ther. 2003;5:139-46.



Nussenblatt RB. Bench to bedside: new approaches to the immunotherapy of uveitic disease. Int Rev Immunol. 2002;21:273-89.



Andrews J, Haskard DO. Current management options in Behcet's disease. Minerva Med. 2002;93:335-45.



Goker B, Goker H. Current therapy for Behcet's disease. Am J Ther. 2002;9:465-70.



Shek LP, Lim DL. Thalidomide in Behcet's disease. Biomed Pharmacother. 2002;56:31-35.



Bang D. Clinical spectrum of Behcet's disease. J Dermatol. 2001;28:610-13.



Calamia KT, Schirmer M, Melikoglu M. Major vessel involvement in Behçet disease. Curr Opin Rheumatol 2005 Jan; 17(1):1-8.



JOURNAL ARTICLES

Tugal-Tutkin I, Urgancioglu M. Childhood-onset uveitis in Behcet disease: a descriptive study of 36 cases. Am J Ophthalmol. 2003;136:1114-19



Inomata H, Yoshikawa H, Rao NA. Phacoanaphylaxis in Behcet's disease: a clinicopathologic and immunohistochemical study. Ophthalmology. 2003; 110:1942-45.



Altiparmak MR, et al. Glomerulonephritis in Behcet's disease: report of seven cases and review of the literature. Clin Rheumatol. 2002;21:14-18.



Filali-Ansary N, et al. Behcet disease. 162 cases. Ann Med Interne. 1999;150:178-88.



FROM THE INTERNET



Hatemi, G., Silman, A., Bang, D. EULAR recommendations for the management of Behcet's disease: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis January 31, 2008, 10.1136/ard.2007.080432



NINDS Behcet's Disease Information Page. Reviewed 09-04-2003. 2pp.

www.ninds.nih.gov/health_and_medical/disorders/behcet_doc.htm



Questions and Answers About Behcet's Disease. NIAMS National Institute of Arthritis and Musculoskeletal and Skin Diseases. Publication Date: January 1999. 8pp.

www.niams.nih.gov/hi/topics/behcets.htm



Lisse. JR. Behcet Disease. emedicine. Last Updated: March 1, 2004. 23pp.

www.emedicine.com/med/topic218.htm



Lee S, Bang D. Behcet Disease.emedicine. Last Updated: February 18, 2004. 25pp.

www.emedicine.com/derm/topic/topic49.htm



American Behcet's Disease Association. ABDA.

Diagnosis. Last Updated: November 8, 2002. 2pp.

Most Common Symptoms and Signs. Last Updated April 1, 2002. 2pp

www.behcets.com

Resources

American Behcet's Disease Association

P.O. Box 869

Smithtown, NY 11787-0869

USA

Tel: (631)656-0537

Fax: (480)247-5377

Tel: (800)723-4238

Email: mgiannitelli@behcets.com

Internet: http://www.behcets.com



Vasculitis Foundation

PO Box 28660

Kansas City, MO 64188

USA

Tel: (816)436-8211

Fax: (816)436-8211

Tel: (800)277-9474

Email: vf@vasculitisfoundation.org

Internet: http://www.vasculitisfoundation.org



Lighthouse International

827 Irma Avenue

Orlando, FL 32803

Tel: (212)821-9200

Fax: (212)821-9707

Tel: (800)829-0500

Email: info@lighthouse.org

Internet: http://www.lighthouse.org



American Autoimmune Related Diseases Association, Inc.

15475 Gratiot Avenue

Detroit, MI 48205

Tel: (586)776-3900

Fax: (586)776-3903

Tel: (800)598-4668

Email: aarda@aarda.org

Internet: http://www.aarda.org/



Arthritis Foundation

1314 Spring Street NW

Atlanta, GA 30309

USA

Tel: (404)965-7627

Tel: (800)283-7800

Email: arthritisfoundation@arthritis.org

Internet: http://www.arthritis.org



NIH/NationaI Institute of Arthritis and Musculoskeletal and Skin Diseases

Information Clearinghouse

One AMS Circle

Bethesda, MD 20892-3675

USA

Tel: (301)495-4484

Fax: (301)718-6366

Tel: (877)226-4267

TDD: (301)565-2966

Email: NIAMSinfo@mail.nih.gov

Internet: http://www.niams.nih.gov/



NIH/National Eye Institute

31 Center Dr

MSC 2510

Bethesda, MD 20892-2510

United States

Tel: (301)496-5248

Fax: (301)402-1065

Email: 2020@nei.nih.gov

Internet: http://www.nei.nih.gov/



National Institute of Neurological Disorders and Stroke

P.O. Box 5801

Bethesda, MD 20824

Tel: (301)496-5751

Fax: (301)402-2186

Tel: (800)352-9424

TDD: (301)468-5981

Email: me20t@nih.gov

Internet: http://www.ninds.nih.gov/



Behcet's Organisation Worldwide

PO Box 27

Watchet

Somerset

United Kingdom

Intl TA23 0YJ

Tel: 07713 220303

Email: information@behcetsuk.org

Internet: http://www.behcets.org



MUMS National Parent-to-Parent Network

150 Custer Court

Green Bay, WI 54301-1243

USA

Tel: (920)336-5333

Fax: (920)339-0995

Tel: (877)336-5333

Email: mums@netnet.net

Internet: http://www.netnet.net/mums/



Erythema Nodosum Yahoo Support Group

Internet: http://health.groups.yahoo.com/group/erythema_nodosum_Group/



CNS Vasculitis Foundation

9930 Morningfield

San Antonio, TX 78250-3743

USA

Tel: (210)523-8234

Email: info@cnsvf.org

Internet: http://www.cnsvf.org



Genetic and Rare Diseases (GARD) Information Center

PO Box 8126

Gaithersburg, MD 20898-8126

Tel: (301)251-4925

Fax: (301)251-4911

Tel: (888)205-2311

TDD: (888)205-3223

Email: http://rarediseases.info.nih.gov/GARD/EmailForm.aspx

Internet: http://rarediseases.info.nih.gov/GARD



Madisons Foundation

PO Box 241956

Los Angeles, CA 90024

Tel: (310)264-0826

Fax: (310)264-4766

Email: getinfo@madisonsfoundation.org

Internet: http://www.madisonsfoundation.org



Autoimmune Information Network, Inc

PO Box 4121

Brick, NJ 08723

Tel: (732)664-9259

Fax: (732)543-7285

Email: autoimmunehelp@aol.com

Internet: http://www.aininc.org



European Society for Immunodeficiencies

1-3 rue de Chantepoulet

Geneva 1

Switzerland

CH 1211

Tel: +31 73-6992965

Fax: +41 22 906 91 40

Email: esid@kenes.com

Internet: http://www.esid.org



AutoImmunity Community

Tel: (919) 552-9057

Email: moderator@autoimmunitycommunity.org

Internet: http://www.autoimmunitycommunity.org



For a Complete Report

For a Complete Report

This is an abstract of a report from the National Organization for Rare Disorders, Inc. ® (NORD). A copy of the complete report can be obtained for a small fee by visiting the NORD website. The complete report contains additional information including symptoms, causes, affected population, related disorders, standard and investigational treatments (if available), and references from medical literature. For a full-text version of this topic, see http://www.rarediseases.org/search/rdblist.html

This information does not replace the advice of a doctor. Healthwise, Incorporated disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use. How this information was developed to help you make better health decisions.

Latest Dermatology News
Smoking tied to higher psoriasis risk

February 2, 2012 — NEW YORK (Reuters Health) - Adding to the list of possible health consequences from smoking, a large study suggests that smokers have an increased risk of developing the chronic skin condition psoriasis.

Overweight linked to acne in teen girls

January 20, 2012 — NEW YORK (Reuters Health) - Overweight girls in their late teens were twice as likely as their normal-weight peers to report having a lot of acne in a large new survey of Norwegian teenagers that did not find the same link in boys.

U.S. indoor tanning tax having mixed effects

January 19, 2012 — NEW YORK (Reuters Health) - Although a 2010 federal excise tax was meant to deter customers from using indoor tanning salons, only a minority of the businesses taking part in a new survey reported a drop in clients and most said their customers did not seem to care.

Select news items provided by Reuters Health